GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCryst Pharmaceuticals Inc (MEX:BCRX) » Definitions » Change In Other Working Capital

BioCryst Pharmaceuticals (MEX:BCRX) Change In Other Working Capital : MXN-7 Mil (TTM As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is BioCryst Pharmaceuticals Change In Other Working Capital?

BioCryst Pharmaceuticals's Change In Other Working Capital for the quarter that ended in Sep. 2024 was MXN0 Mil. It means BioCryst Pharmaceuticals's Other Working Capital increased by MXN0 Mil from Jun. 2024 to Sep. 2024 .

BioCryst Pharmaceuticals's Change In Other Working Capital for the fiscal year that ended in Dec. 2023 was MXN-21 Mil. It means BioCryst Pharmaceuticals's Other Working Capital declined by MXN21 Mil from Dec. 2022 to Dec. 2023 .

BioCryst Pharmaceuticals Change In Other Working Capital Historical Data

The historical data trend for BioCryst Pharmaceuticals's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCryst Pharmaceuticals Change In Other Working Capital Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Other Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.82 -39.19 26.32 -2.13 -20.88

BioCryst Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Change In Other Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.45 -7.11 - - -

BioCryst Pharmaceuticals Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioCryst Pharmaceuticals Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

BioCryst Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCryst Pharmaceuticals Inc (MEX:BCRX) » Definitions » Change In Other Working Capital
Comparable Companies
NMRA NRIX TVTX VRDN SYRE NTLA BCYC XNCR PRAX OCUL VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
BCRX:USA BO1:Germany BO1:Germany
Address
4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
Website
https://www.biocryst.com
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.